Brian A. Whiteman

Array ( [id] => 18117730 [patent_doc_number] => 11549112 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-01-10 [patent_title] => RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use [patent_app_type] => utility [patent_app_number] => 17/748779 [patent_app_country] => US [patent_app_date] => 2022-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49255 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17748779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18229345 [patent_doc_number] => 20230068339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/741550 [patent_app_country] => US [patent_app_date] => 2022-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17741550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960327 [patent_doc_number] => 20220340907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => OLIGONUCLEOTIDES FOR TREATMENT OF ANGIOPOIETIN LIKE 4 (ANGPTL4) RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/736928 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552428 [patent_doc_number] => 20230250437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => OLIGONUCLEOTIDE PROBES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/727263 [patent_app_country] => US [patent_app_date] => 2022-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 109481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020977 [patent_doc_number] => 20220372476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => DYNAMIC PHARMACOKINETIC-MODIFYING ANCHORS [patent_app_type] => utility [patent_app_number] => 17/725102 [patent_app_country] => US [patent_app_date] => 2022-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982888 [patent_doc_number] => 20220348924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => BISPECIFIC APTAMER FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/719189 [patent_app_country] => US [patent_app_date] => 2022-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17719189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18485232 [patent_doc_number] => 20230212563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => Methods and Systems of Molecular Recording by Crispr-Cas System [patent_app_type] => utility [patent_app_number] => 17/717283 [patent_app_country] => US [patent_app_date] => 2022-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17717283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036560 [patent_doc_number] => 20220380775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/714272 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17928481 [patent_doc_number] => 20220323606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => Targeting Technology to Selectively Express mRNAs in Cardiomyocytes While Avoiding Stimulation of Cardiac Fibroblasts [patent_app_type] => utility [patent_app_number] => 17/711125 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036557 [patent_doc_number] => 20220380772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) [patent_app_type] => utility [patent_app_number] => 17/711114 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53106 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701731 [patent_doc_number] => 12195746 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue [patent_app_type] => utility [patent_app_number] => 17/706522 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 23 [patent_no_of_words] => 21365 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17706522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17735042 [patent_doc_number] => 20220220501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => CELL-SPECIFIC EXPRESSION OF modRNA [patent_app_type] => utility [patent_app_number] => 17/705609 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18871399 [patent_doc_number] => 11859188 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => DNA aptamer, pharmaceutical composition comprising same, method for inhibiting catalytic ability of TXNDC5, and method for preventing or treating organ fibrosis [patent_app_type] => utility [patent_app_number] => 17/705421 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 30 [patent_no_of_words] => 8207 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897394 [patent_doc_number] => 20220307056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => TETRACYCLINE-INDUCIBLE EXPRESSION SYSTEMS [patent_app_type] => utility [patent_app_number] => 17/700405 [patent_app_country] => US [patent_app_date] => 2022-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17700405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19923235 [patent_doc_number] => 12297506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => High performance multi-input microRNA sensors and uses thereof [patent_app_type] => utility [patent_app_number] => 17/688985 [patent_app_country] => US [patent_app_date] => 2022-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 60 [patent_no_of_words] => 19648 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 280 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761743 [patent_doc_number] => 20220235355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS [patent_app_type] => utility [patent_app_number] => 17/678433 [patent_app_country] => US [patent_app_date] => 2022-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12838 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17678433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18027836 [patent_doc_number] => 11510997 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Treatment of primary ciliary dyskinesia with synthetic messenger RNA [patent_app_type] => utility [patent_app_number] => 17/668346 [patent_app_country] => US [patent_app_date] => 2022-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 38 [patent_no_of_words] => 27806 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807819 [patent_doc_number] => 20220259654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => COMPOSITIONS AND METHODS FOR XI CHROMOSOME REACTIVATION [patent_app_type] => utility [patent_app_number] => 17/585765 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17585765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18162634 [patent_doc_number] => 20230029227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => TUNABLE REVERSIR TM COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/583931 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792464 [patent_doc_number] => 20220251555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 17/580269 [patent_app_country] => US [patent_app_date] => 2022-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17580269 [rel_patent_id] =>[rel_patent_doc_number] =>)